CXCR4 and neoplasm: Current phase I/II study showed that CXCR4 inhibitor Plerixafor was well tolerated as an adjunct to chemoirradiation in newly diagnosed glioblastoma patients and reduced tumor local recurrences by inhibiting postirradiation tumor revascularization (177).